A Clinical Trial To Evaluate The Safety And Efficacy Of Saroglitazar Compared To Fenofibrate In Patients With Dyslipidemia

Parmar, Deven; Krishnappa, Manjunath; Arifahmed, F.; Mali, Niroj; Patel, Jatin; Shah, Monarch; Parmar, Krupi; Shah, Chitrang; Faldu, Khushboo

doi:10.1016/j.atherosclerosis.2019.06.105

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to this study, a randomized control trial was conducted by Parmar et al, which assessed the efficacy of saroglitazar and fenofibrate. The study found that both drugs were effective in achieving target lipid levels [ 10 ]. However, saroglitazar was more effective than fenofibrate in controlling lipid levels.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Furthermore, combining statins and fibrates is more effective in limiting atherogenic dyslipidemia as compared to monotherapy [ 9 ]. Fenofibrate induces an elevation in lipase activity and a reduction in cholesterol ester transport protein function via activating peroxisome proliferator-activated receptors [ 10 ]. The outcome is a decline in triglycerides (TG) levels, a change in low-density lipoprotein (LDL) particle size, and an increase in high-density lipoprotein (HDL) cholesterol.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Efficacy of Fenofibrate in Addition to Atorvastatin in Patients of Type II Diabetes Mellitus

Qasim¹,

Khan²,

Rahman³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundThe objective was to study the efficacy of atorvastatin in combination with fenofibrate as compared to atorvastatin in combination with saroglitazar in patients of diabetes mellitus type II with dyslipidemia. MethodologyA quasi-experimental study was done at the Diabetes and Endocrinology Ward, Hayatabad Medical Complex Peshawar, between January 2021 to June 2021. All patients aged 25 years and above with newly diagnosed diabetes mellitus (less than six months ago) with dyslipidemia, i.e., deranged lipid range, were eligible to participate. Patients with secondary hypertension, pregnancy, or any pulmonary disease were excluded from the study. Patients already taking anti-glycemic drugs were also ineligible to participate. Patients were divided into two groups. Group I patients received Atorvastatin 10mg plus Fenofibrate 145 mg, while Group II received the combination of the tab. Atorvastatin 10mg in addition to Saroglitazar 4g. Lipid profiles were studied at baseline and 24-month follow-up. All data were documented in a preformed proforma. ResultsA total of 80 patients were enrolled in the study, with 40 patients in each group. In Group I (atorvastatin + fenofibrate), the mean cholesterol at 24-week follow-up was 254.51 ± 47.41 as compared to 230.45 ± 47.21 in Group II (p<0.0001). Similarly, total triglycerides, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) were significantly higher in Group I patients by 24-week follow-up as compared to Group II. The mean HDL levels in Group I changed from 40.21 ± 3.54 at baseline to 46.28 ± 6.25 at follow-up, while in Group II, the mean HDL levels altered from 39.54 ± 4.52 to 52.34 ± 7.54 (p<0.0001). ConclusionOverall, both groups showed significant improvements in lipid profiles; however, when atorvastatin in addition to fenofibrate was compared with saroglitazar, it was found that the latter combination was more effective in improving the overall patient outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%